Glutoborin
Glutoborin is an orally active GLUT1-specific proteasome inhibitor with a Kd value of 119 nM for GLUT1. Glutoborin binds to GLUT1, inhibits proteasome activity, restricts IκBα degradation, blocks NF-κB activation, and inhibits GLUT1-mediated glucose transport to elevate blood glucose levels. Glutoborin inhibits pro-inflammatory gene expression, B cell activation, autoantibody production and macrophage function, disrupts the interaction between macrophages and B cells, and alleviates systemic inflammation, neuroinflammation and blood-brain barrier damage. Glutoborin can be used in research related to cerebral malaria.
For research use only. We do not sell to patients.
- Formula: C34H44BCl2N5O4
- Molecular Weight:668.46
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GLUT1 119 nM (Kd) |
In Vitro
Glutoborin (0.049-6.25 μM; association time 0s, dissociation time 60s) binds purified GLUT1 protein with a dissociation constant KD of 119 nM[1].
Glutoborin exhibits high binding affinity for GLUT1, as demonstrated by a docking score of -12.52 in in silico assays[2].
Glutoborin (100 nM; 3 hours) potently inhibits proteasome activity in HEK293T cells[1].
Glutoborin (100 nM; 3 h wild-type, 30 min transfected 24 h prior) selectively inhibits proteasome activity in GLUT1-expressing HEK293T cells, with enhanced inhibition in cells expressing the membrane-localized GLUT1S226D mutant[2].
Glutoborin (49-6250 nM; 30 minutes) inhibits proteasome activity in a GLUT1-dependent manner, as GLUT1-knockdown 4T1 cells are resistant to its effects while wild-type 4T1 cells show concentration-dependent inhibition[1].
Glutoborin (20 nM; 12 hours post 12-hour LPS/IFNγ stimulation) inhibits proteasome activity and reduces Tnf expression in LPS/IFNγ-stimulated RAW264.7 macrophages[1].
Glutoborin (20 nM; 12 h) suppresses pro-inflammatory gene (Tnf, Il6) expression in LPS/IFN-γ-stimulated RAW264.7 macrophages[2].
Glutoborin (2-hour pretreatment, followed by 30-minute LPS/IFNγ stimulation) limits IκBα degradation by restricting proteasome activity, thereby suppressing downstream NF-κB activation in RAW264.7 macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 macrophages (LPS/IFN-γ-stimulated)
-
Concentration:20 nM
-
Incubation Time:12 h (following 12 h of LPS/IFN-γ stimulation)
-
Result:Markedly suppressed the expression of the pro-inflammatory genes *Tnf* and *Il6* in activated RAW264.7 macrophages.
In Vivo
Glutoborin (10 mg/kg; i.v.; 3 doses (days 2, 4, 6 post-infection)) treatment confers 100% survival in Plasmodium berghei ANKA-infected mice, while suppressing pathogenic B cell activation, autoantibody production, and systemic and neuroinflammation[2].
Glutoborin (10 mg/kg; i.v.; 3 doses (days 0, 2, 4)) exhibits superior in vivo safety in healthy mice[2].
Glutoborin (1-10 mg/kg; i.v., p.o.; single dose) demonstrates broad tissue distribution, rapid absorption, and moderate clearance in healthy male Sprague-Dawley rats following single intravenous (1 mg/kg) or oral (10 mg/kg) administration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 6-8 weeks old, Plasmodium berghei ANKA infection)[1]
-
Dosage:10 mg/kg
-
Administration:administered on days 2, 4, and 6 post-infection
-
Result:Conferred 100% survival.
Maintained platelet counts within normal physiological ranges.
Reduced blood-brain barrier disruption measured by Evans blue dye extravasation OD620.
Decreased cerebral hemorrhagic area.
Lowered brain expression of pro-inflammatory genes Cxcl10, Isg15, and Tnf.
Significantly reduced serum total IgM levels on days 4, 5, and 6 post-infection.
Significantly reduced anti-platelet IgM levels on day 7 post-infection.
Ameliorated splenomegaly.
Reduced the frequency and absolute number of splenic Ly6c+Ccr2+ macrophages.
Decreased the proportion of activated splenic B cells.
Suppressed gene programs associated with vesicle-mediated exocytosis and IFN-I signaling in macrophages.
Reduced Isg15 and Ifit2 expression in sorted splenic Ly6c+Ccr2+ macrophages.
Reduced hepatic and cardiac toxicity.
Promoted more rapid weight recovery compared to bortezomib-treated controls.
-
Animal Model:C57BL/6J (male, 6-8 weeks old, cerebral malaria model via intraperitoneal injection of 1 × 104 Plasmodium berghei ANKA-infected red blood cells)[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; 3 doses (days 2, 4, 6 post-infection)
-
Result:Conferred 100% survival of infected mice.
Maintained platelet counts within normal physiological parameters.
Significantly reduced blood-brain barrier disruption (measured by decreased Evans blue extravasation).
Lowered expression of pro-inflammatory genes Cxcl10, Isg15, and Tnf in brain tissue.
Reduced peripheral parasitemia.
Restored normoglycemia.
Ameliorated splenomegaly.
Suppressed expansion of marginal zone B cells.
Lowered CD19+CD69+ activated B cell percentages.
Reduced total serum IgM and anti-platelet IgM levels.
-
Animal Model:C57BL/6J (male, 6-8 weeks old)[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; 3 doses (days 0, 2, 4)
-
Result:Showed significantly lower liver and cardiac toxicity compared to bortezomib-treated controls.
Enabled rapid weight recovery to baseline levels.
-
Animal Model:Sprague-Dawley (male)[2]
-
Dosage:1 mg/kg (i.v.); 10 mg/kg (p.o.)
-
Administration:i.v.; single dose; p.o.; single dose
-
Result:Achieved an initial plasma concentration above 100 ng/mL, which declined to approximately 2 ng/mL at 24 hours following intravenous administration of 1 mg/kg.
Reached an initial plasma concentration around 50 ng/mL, which declined to approximately 1 ng/mL at 24 hours following oral administration of 10 mg/kg.
Chemical Information
-
Molecular Weight 668.46
-
Formula C34H44BCl2N5O4
-
SMILES
CC(C)C[C@@H](B(O)O)NC(CN1C(C2=CC=CC=C2)=CC(C3=CC(OCCN(CC4)CCN4C5=CC=CC=C5)=CC=C3)=N1)=O.Cl.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)